Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Editorial: How Do Metabolism, Angiogenesis, and Hypoxia Modulate Resistance?

  • Kondoh, Hiroshi
  • Castellví Vives, Josep
  • Lleonart Pajarin, Matilde
Resistència al càncer; Cèl·lules mare cancerígenes; Teràpia, Resistencia al cáncer; Células madre cancerosas; Terapia, Cancer resistance; Cancer stem cell; Therapy, Metabolic alterations were among the first discovered hallmarks of cancer. They were first described 90 years ago when Otto Warburg realized that cancer cells in culture had a relatively increased metabolic rate (the Warburg hypothesis). It has been proposed that the drastic changes seen in cancer metabolism are in part attributed to mutations in the mtDNA, metabolic reprogramming, or mitochondrial dysfunction. However, novel players in cancer metabolism are emerging., This work was supported by ISCIII (Instituto de Salud Carlos III) Ref. FIS PI15/01262 (MELL), co-financed by the European Regional Development Fund (ERDF) and AECC Project GEC Ref. GC16173720CARR (MELL).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

SDCBP Modulates Stemness and Chemoresistance in Head and Neck Squamous Cell Carcinoma through Src Activation

  • Mir Perez, Cristina
  • García Murias, Laia
  • Herrero, Pol
  • Canela, Nuria
  • Tabernero, Rocio
  • Lorente Guerrero, Juan
  • Castellví Vives, Josep
  • Lleonart Pajarin, Matilde
  • Garcia Mayea, Yoelsis
Cèl·lules mare del càncer; Quimioresistència, Células madre del cáncer; Quimiorresistencia, Cancer stem cells; Chemoresistance, To characterize the mechanisms that govern chemoresistance, we performed a comparative proteomic study analyzing head and neck squamous cell carcinoma (HNSCC) cells: CCL-138 (parental), CCL-138-R (cisplatin-resistant), and cancer stem cells (CSCs). Syntenin-1 (SDCBP) was upregulated in CCL-138-R cells and CSCs over parental cells. SDCBP depletion sensitized biopsy-derived and established HNSCC cell lines to cisplatin (CDDP) and reduced CSC markers, Src activation being the main SDCBP downstream target. In mice, SDCBP-depleted cells formed tumors with decreased mitosis, Ki-67 positivity, and metastasis over controls. Moreover, the fusocellular pattern of CCL-138-R cell-derived tumors reverted to a more epithelial morphology upon SDCBP silencing. Importantly, SDCBP expression was associated with Src activation, poor differentiated tumor grade, advanced tumor stage, and shorter survival rates in a series of 382 HNSCC patients. Our results reveal that SDCBP might be a promising therapeutic target for effectively eliminating CSCs and CDDP resistance., This research was supported by grants from the Instituto de Salud Carlos III (ISCIII): PI15/01262 and CP03/00101 (M.E.LL.), PI19/00560 (J.G.-P.), and CIBERONC (M.E.LL. and IDI2018/155 J.P.R.) and was co-financed by the European Regional Fund (ERDF) and AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR (M.E.LL.). Y.G.M. and C.M. were supported by the VHIR and iP-FIS (ISCIII) fellowships, respectively. We acknowledge the Principado de Asturias BioBank (PT17/0015/0023).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

TSPAN1: A Novel Protein Involved in Head and Neck Squamous Cell Carcinoma Chemoresistance

  • Mir Perez, Cristina
  • Carballo Perich, Laia
  • Castellví Vives, Josep
  • Lorente Guerrero, Juan
  • Benavente Norza, Sergio
  • Lleonart Pajarin, Matilde
  • Temprana Salvador, Jordi
  • Garcia Mayea, Yoelsis
Apoptosi; Cèl·lules mare del càncer; Resistència, Apoptosis; Células madre cancerosas; Resistencia, Apoptosis; Cancer stem cells; Resistance, Sensitization of resistant cells and cancer stem cells (CSCs) represents a major challenge in cancer therapy. A proteomic study revealed tetraspanin-1 (TSPAN1) as a protein involved in acquisition of cisplatin (CDDP) resistance (Data are available via ProteomeXchange with identifier PXD020159). TSPAN1 was found to increase in CDDP-resistant cells, CSCs and biopsies from head and neck squamous cell carcinoma (HNSCC) patients. TSPAN1 depletion in parental and CDDP-resistant HNSCC cells reduced cell proliferation, induced apoptosis, decreased autophagy, sensitized to chemotherapeutic agents and inhibited several signaling cascades, with phospho-SRC inhibition being a major common target. Moreover, TSPAN1 depletion in vivo decreased the size and proliferation of parental and CDDP-resistant tumors and reduced metastatic spreading. Notably, CDDP-resistant tumors showed epithelial–mesenchymal transition (EMT) features that disappeared upon TSPAN1 inhibition, suggesting a link of TSPAN1 with EMT and metastasis. Immunohistochemical analysis of HNSCC specimens further revealed that TSPAN1 expression was correlated with phospho-SRC (pSRC), and inversely with E-cadherin, thus reinforcing TSPAN1 association with EMT. Overall, TSPAN1 emerges as a novel oncogenic protein and a promising target for HNSCC therapy., This work was supported by grants from the Instituto de Salud Carlos III (ISCIII): PI15/01262 (M.E.LL.) PI19/00560 (J.M.G.-P.) and CP03/00101 (M.E.L.), CIBERONC (CB16/12/00390 to J.P.R.), Ayudas a Grupos PCTI Principado de Asturias (IDI2018/155 to J.P.R.), co-financed by the European Regional Fund (ERDF) and AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR (M.E.L.). Y.G.-M. and C.M. were granted by the VHIR and iP-FIS (ISCIII) fellowships respectively.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Therapy-Induced Modulation of the Tumor Microenvironment: New Opportunities for Cancer Therapies

  • Benavente Norza, Sergio
  • Sanchez Garcia, Almudena
  • Naches Garcia, Silvia
  • Lorente Guerrero, Juan
  • Lleonart Pajarin, Matilde
Càncer; Immunoteràpia; Radioteràpia, Cáncer; Inmunoterapia; Radioterapia, Cancer; Immunotherapy; Radiotherapy, Advances in immunotherapy have achieved remarkable clinical outcomes in tumors with low curability, but their effects are limited, and increasing evidence has implicated tumoral and non-tumoral components of the tumor microenvironment as critical mediators of cancer progression. At the same time, the clinical successes achieved with minimally invasive and optically-guided surgery and image-guided and ablative radiation strategies have been successfully implemented in clinical care. More effective, localized and safer treatments have fueled strong research interest in radioimmunotherapy, which has shown the potential immunomodulatory effects of ionizing radiation. However, increasingly more observations suggest that immunosuppressive changes, metabolic remodeling, and angiogenic responses in the local tumor microenvironment play a central role in tumor recurrence. In this review, we address challenges to identify responders vs. non-responders to the immune checkpoint blockade, discuss recent developments in combinations of immunotherapy and radiotherapy for clinical evaluation, and consider the clinical impact of immunosuppressive changes in the tumor microenvironment in the context of surgery and radiation. Since the therapy-induced modulation of the tumor microenvironment presents a multiplicity of forms, we propose that overcoming microenvironment related resistance can become clinically relevant and represents a novel strategy to optimize treatment immunogenicity and improve patient outcome., This work was supported by grants from the Instituto de Salud Carlos III (ISCIII): PI15/01262 (ML) and CP03/00101 (ML), co-financed by the European Regional Fund (ERDF) and AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR (ML). AS-G was granted by VHIR fellowships.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals

  • Feliciano Aguirre, Andrea F
  • Gonzalez Amaya, Lucila
  • Mir Perez, Cristina
  • Artola, Mireia
  • Barragán, Nieves
  • Castellví Vives, Josep
  • Benavente Norza, Sergio
  • Ramon y Cajal Agüeras, Santiago
  • Espinosa Bravo, Martin
  • Cortés Castan, Javier
  • Lleonart Pajarin, Matilde
  • Garcia Mayea, Yoelsis
Càncer de mama; Diagnòstic; Sèrum, Cáncer de mama; Diagnóstico; Suero, Breast cancer; Diagnosis; Serum, Breast cancer is the cancer with the most incidence and mortality in women. microRNAs are emerging as novel prognosis/diagnostic tools. Our aim was to identify a serum microRNA signature useful to predict cancer development. We focused on studying the expression levels of 30 microRNAs in the serum of 96 breast cancer patients vs. 92 control individuals. Bioinformatic studies provide a microRNA signature, designated as a predictor, based on the expression levels of five microRNAs. Then, we tested the predictor in a group of 60 randomly chosen women. Lastly, a proteomic study unveiled the overexpression and downregulation of proteins differently expressed in the serum of breast cancer patients vs. that of control individuals. Twenty-six microRNAs differentiate cancer tissue from healthy tissue, and 16 microRNAs differentiate the serum of cancer patients from that of the control group. The tissue expression of miR-99a, miR-497, miR-362, and miR-1274, and the serum levels of miR-141 correlated with patient survival. Moreover, the predictor consisting of miR-125b, miR-29c, miR-16, miR-1260, and miR-451 was able to differentiate breast cancer patients from controls. The predictor was validated in 20 new cases of breast cancer patients and tested in 60 volunteer women, assigning 11 out of 60 women to the cancer group. An association of low levels of miR-16 with a high content of CD44 protein in serum was found. Circulating microRNAs in serum can represent biomarkers for cancer prediction. Their clinical relevance and the potential use of the predictor here described are discussed., This work was supported by ISCIII (Instituto de Salud Carlos III) Ref. FIS PI15/01262, co-financed by the European Regional Development Fund (ERDF) and AECC Project GEC Ref. GC16173720CARR (ML). AF, YG-M, and CM were granted with P-FIS, VHIR, and iP-FIS fellowships, respectively.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

TSPAN1, a Novel Protein Involved in Head and Neck Squamous Cell Carcinoma Chemoresistance

  • Garcia Mayea, Yoelsis|||0000-0002-9395-7471
  • Mir Pérez, Cristina|||0000-0003-3137-6521
  • Carballo, Laia
  • Castellvi, Josep|||0000-0001-5745-9996
  • Temprana-Salvador, Jordi|||0000-0001-9516-1680
  • Lorente Guerrero, Juan|||0000-0002-3264-0251
  • Benavente, Sergi|||0000-0002-2700-3522
  • García-Pedrero, Juana María|||0000-0002-5891-9488
  • Allonca, Eva|||0000-0002-2532-5421
  • Rodrigo, Juan Pablo|||0000-0003-3063-0890
  • Lleonart, Matilde Esther|||0000-0002-6196-7405
Sensitization of resistant cells and cancer stem cells (CSCs) represents a major challenge in cancer therapy. A proteomic study revealed tetraspanin-1 (TSPAN1) as a protein involved in acquisition of cisplatin (CDDP) resistance (Data are available via ProteomeXchange with identifier PXD020159). TSPAN1 was found to increase in CDDP-resistant cells, CSCs and biopsies from head and neck squamous cell carcinoma (HNSCC) patients. TSPAN1 depletion in parental and CDDP-resistant HNSCC cells reduced cell proliferation, induced apoptosis, decreased autophagy, sensitized to chemotherapeutic agents and inhibited several signaling cascades, with phospho-SRC inhibition being a major common target. Moreover, TSPAN1 depletion in vivo decreased the size and proliferation of parental and CDDP-resistant tumors and reduced metastatic spreading. Notably, CDDP-resistant tumors showed epithelial-mesenchymal transition (EMT) features that disappeared upon TSPAN1 inhibition, suggesting a link of TSPAN1 with EMT and metastasis. Immunohistochemical analysis of HNSCC specimens further revealed that TSPAN1 expression was correlated with phospho-SRC (pSRC), and inversely with E-cadherin, thus reinforcing TSPAN1 association with EMT. Overall, TSPAN1 emerges as a novel oncogenic protein and a promising target for HNSCC therapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Therapy-Induced Modulation of the Tumor Microenvironment, New Opportunities for Cancer Therapies

  • Benavente, Sergi|||0000-0002-2700-3522
  • Sánchez García, Almudena
  • Naches Solsona, Silvia
  • Lleonart, Matilde Esther|||0000-0002-6196-7405
  • Lorente Guerrero, Juan|||0000-0002-3264-0251
Advances in immunotherapy have achieved remarkable clinical outcomes in tumors with low curability, but their effects are limited, and increasing evidence has implicated tumoral and non-tumoral components of the tumor microenvironment as critical mediators of cancer progression. At the same time, the clinical successes achieved with minimally invasive and optically-guided surgery and image-guided and ablative radiation strategies have been successfully implemented in clinical care. More effective, localized and safer treatments have fueled strong research interest in radioimmunotherapy, which has shown the potential immunomodulatory effects of ionizing radiation. However, increasingly more observations suggest that immunosuppressive changes, metabolic remodeling, and angiogenic responses in the local tumor microenvironment play a central role in tumor recurrence. In this review, we address challenges to identify responders vs. non-responders to the immune checkpoint blockade, discuss recent developments in combinations of immunotherapy and radiotherapy for clinical evaluation, and consider the clinical impact of immunosuppressive changes in the tumor microenvironment in the context of surgery and radiation. Since the therapy-induced modulation of the tumor microenvironment presents a multiplicity of forms, we propose that overcoming microenvironment related resistance can become clinically relevant and represents a novel strategy to optimize treatment immunogenicity and improve patient outcome.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

SDCBP modulates stemness and chemoresistance in head and neck squamous cell carcinoma through src activation

  • Mir Pérez, Cristina|||0000-0003-3137-6521
  • Garcia Mayea, Yoelsis|||0000-0002-9395-7471
  • García Fernández, Laia|||0009-0008-3105-493X
  • Herrero, Pol|||0000-0002-8746-7214
  • Canela, Núria|||0000-0003-0261-2396
  • Tabernero, Rocío|||0000-0002-5949-0898
  • Lorente Guerrero, Juan|||0000-0002-3264-0251
  • Castellvi, Josep|||0000-0001-5745-9996
  • Allonca, Eva|||0000-0002-2532-5421
  • García-Pedrero, Juana
  • Rodrigo, Juan Pablo|||0000-0003-3063-0890
  • Carracedo, Ángel|||0000-0003-1085-8986
  • Lleonart, Matilde Esther|||0000-0002-6196-7405
To characterize the mechanisms that govern chemoresistance, we performed a comparative proteomic study analyzing head and neck squamous cell carcinoma (HNSCC) cells: CCL-138 (parental), CCL-138-R (cisplatin-resistant), and cancer stem cells (CSCs). Syntenin-1 (SDCBP) was upregulated in CCL-138-R cells and CSCs over parental cells. SDCBP depletion sensitized biopsy-derived and established HNSCC cell lines to cisplatin (CDDP) and reduced CSC markers, Src activation being the main SDCBP downstream target. In mice, SDCBP-depleted cells formed tumors with decreased mitosis, Ki-67 positivity, and metastasis over controls. Moreover, the fusocellular pattern of CCL-138-R cell-derived tumors reverted to a more epithelial morphology upon SDCBP silencing. Importantly, SDCBP expression was associated with Src activation, poor differentiated tumor grade, advanced tumor stage, and shorter survival rates in a series of 382 HNSCC patients. Our results reveal that SDCBP might be a promising therapeutic target for effectively eliminating CSCs and CDDP resistance.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

TSPAN1: A Novel Protein Involved in Head and Neck Squamous Cell Carcinoma Chemoresistance

  • Mir Perez, Cristina
  • Carballo Perich, Laia
  • Castellví Vives, Josep
  • Lorente Guerrero, Juan
  • Benavente Norza, Sergio
  • Lleonart Pajarin, Matilde
  • Temprana Salvador, Jordi
  • Garcia Mayea, Yoelsis
Apoptosi; Cèl·lules mare del càncer; Resistència, Apoptosis; Células madre cancerosas; Resistencia, Apoptosis; Cancer stem cells; Resistance, Sensitization of resistant cells and cancer stem cells (CSCs) represents a major challenge in cancer therapy. A proteomic study revealed tetraspanin-1 (TSPAN1) as a protein involved in acquisition of cisplatin (CDDP) resistance (Data are available via ProteomeXchange with identifier PXD020159). TSPAN1 was found to increase in CDDP-resistant cells, CSCs and biopsies from head and neck squamous cell carcinoma (HNSCC) patients. TSPAN1 depletion in parental and CDDP-resistant HNSCC cells reduced cell proliferation, induced apoptosis, decreased autophagy, sensitized to chemotherapeutic agents and inhibited several signaling cascades, with phospho-SRC inhibition being a major common target. Moreover, TSPAN1 depletion in vivo decreased the size and proliferation of parental and CDDP-resistant tumors and reduced metastatic spreading. Notably, CDDP-resistant tumors showed epithelial–mesenchymal transition (EMT) features that disappeared upon TSPAN1 inhibition, suggesting a link of TSPAN1 with EMT and metastasis. Immunohistochemical analysis of HNSCC specimens further revealed that TSPAN1 expression was correlated with phospho-SRC (pSRC), and inversely with E-cadherin, thus reinforcing TSPAN1 association with EMT. Overall, TSPAN1 emerges as a novel oncogenic protein and a promising target for HNSCC therapy., This work was supported by grants from the Instituto de Salud Carlos III (ISCIII): PI15/01262 (M.E.LL.) PI19/00560 (J.M.G.-P.) and CP03/00101 (M.E.L.), CIBERONC (CB16/12/00390 to J.P.R.), Ayudas a Grupos PCTI Principado de Asturias (IDI2018/155 to J.P.R.), co-financed by the European Regional Fund (ERDF) and AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR (M.E.L.). Y.G.-M. and C.M. were granted by the VHIR and iP-FIS (ISCIII) fellowships respectively.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

SDCBP Modulates Stemness and Chemoresistance in Head and Neck Squamous Cell Carcinoma through Src Activation

  • Mir Perez, Cristina
  • García Murias, Laia
  • Herrero, Pol
  • Canela, Nuria
  • Tabernero, Rocio
  • Lorente Guerrero, Juan
  • Castellví Vives, Josep
  • Lleonart Pajarin, Matilde
  • Garcia Mayea, Yoelsis
Cèl·lules mare del càncer; Quimioresistència, Células madre del cáncer; Quimiorresistencia, Cancer stem cells; Chemoresistance, To characterize the mechanisms that govern chemoresistance, we performed a comparative proteomic study analyzing head and neck squamous cell carcinoma (HNSCC) cells: CCL-138 (parental), CCL-138-R (cisplatin-resistant), and cancer stem cells (CSCs). Syntenin-1 (SDCBP) was upregulated in CCL-138-R cells and CSCs over parental cells. SDCBP depletion sensitized biopsy-derived and established HNSCC cell lines to cisplatin (CDDP) and reduced CSC markers, Src activation being the main SDCBP downstream target. In mice, SDCBP-depleted cells formed tumors with decreased mitosis, Ki-67 positivity, and metastasis over controls. Moreover, the fusocellular pattern of CCL-138-R cell-derived tumors reverted to a more epithelial morphology upon SDCBP silencing. Importantly, SDCBP expression was associated with Src activation, poor differentiated tumor grade, advanced tumor stage, and shorter survival rates in a series of 382 HNSCC patients. Our results reveal that SDCBP might be a promising therapeutic target for effectively eliminating CSCs and CDDP resistance., This research was supported by grants from the Instituto de Salud Carlos III (ISCIII): PI15/01262 and CP03/00101 (M.E.LL.), PI19/00560 (J.G.-P.), and CIBERONC (M.E.LL. and IDI2018/155 J.P.R.) and was co-financed by the European Regional Fund (ERDF) and AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR (M.E.LL.). Y.G.M. and C.M. were supported by the VHIR and iP-FIS (ISCIII) fellowships, respectively. We acknowledge the Principado de Asturias BioBank (PT17/0015/0023).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Editorial: How Do Metabolism, Angiogenesis, and Hypoxia Modulate Resistance?

  • Kondoh, Hiroshi
  • Castellví Vives, Josep
  • Lleonart Pajarin, Matilde
Resistència al càncer; Cèl·lules mare cancerígenes; Teràpia, Resistencia al cáncer; Células madre cancerosas; Terapia, Cancer resistance; Cancer stem cell; Therapy, Metabolic alterations were among the first discovered hallmarks of cancer. They were first described 90 years ago when Otto Warburg realized that cancer cells in culture had a relatively increased metabolic rate (the Warburg hypothesis). It has been proposed that the drastic changes seen in cancer metabolism are in part attributed to mutations in the mtDNA, metabolic reprogramming, or mitochondrial dysfunction. However, novel players in cancer metabolism are emerging., This work was supported by ISCIII (Instituto de Salud Carlos III) Ref. FIS PI15/01262 (MELL), co-financed by the European Regional Development Fund (ERDF) and AECC Project GEC Ref. GC16173720CARR (MELL).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Therapy-Induced Modulation of the Tumor Microenvironment: New Opportunities for Cancer Therapies

  • Benavente Norza, Sergio
  • Sanchez Garcia, Almudena
  • Naches Garcia, Silvia
  • Lorente Guerrero, Juan
  • Lleonart Pajarin, Matilde
Càncer; Immunoteràpia; Radioteràpia, Cáncer; Inmunoterapia; Radioterapia, Cancer; Immunotherapy; Radiotherapy, Advances in immunotherapy have achieved remarkable clinical outcomes in tumors with low curability, but their effects are limited, and increasing evidence has implicated tumoral and non-tumoral components of the tumor microenvironment as critical mediators of cancer progression. At the same time, the clinical successes achieved with minimally invasive and optically-guided surgery and image-guided and ablative radiation strategies have been successfully implemented in clinical care. More effective, localized and safer treatments have fueled strong research interest in radioimmunotherapy, which has shown the potential immunomodulatory effects of ionizing radiation. However, increasingly more observations suggest that immunosuppressive changes, metabolic remodeling, and angiogenic responses in the local tumor microenvironment play a central role in tumor recurrence. In this review, we address challenges to identify responders vs. non-responders to the immune checkpoint blockade, discuss recent developments in combinations of immunotherapy and radiotherapy for clinical evaluation, and consider the clinical impact of immunosuppressive changes in the tumor microenvironment in the context of surgery and radiation. Since the therapy-induced modulation of the tumor microenvironment presents a multiplicity of forms, we propose that overcoming microenvironment related resistance can become clinically relevant and represents a novel strategy to optimize treatment immunogenicity and improve patient outcome., This work was supported by grants from the Instituto de Salud Carlos III (ISCIII): PI15/01262 (ML) and CP03/00101 (ML), co-financed by the European Regional Fund (ERDF) and AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR (ML). AS-G was granted by VHIR fellowships.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals

  • Feliciano Aguirre, Andrea F
  • Gonzalez Amaya, Lucila
  • Mir Perez, Cristina
  • Artola, Mireia
  • Barragán, Nieves
  • Castellví Vives, Josep
  • Benavente Norza, Sergio
  • Ramon y Cajal Agüeras, Santiago
  • Espinosa Bravo, Martin
  • Cortés Castan, Javier
  • Lleonart Pajarin, Matilde
  • Garcia Mayea, Yoelsis
Càncer de mama; Diagnòstic; Sèrum, Cáncer de mama; Diagnóstico; Suero, Breast cancer; Diagnosis; Serum, Breast cancer is the cancer with the most incidence and mortality in women. microRNAs are emerging as novel prognosis/diagnostic tools. Our aim was to identify a serum microRNA signature useful to predict cancer development. We focused on studying the expression levels of 30 microRNAs in the serum of 96 breast cancer patients vs. 92 control individuals. Bioinformatic studies provide a microRNA signature, designated as a predictor, based on the expression levels of five microRNAs. Then, we tested the predictor in a group of 60 randomly chosen women. Lastly, a proteomic study unveiled the overexpression and downregulation of proteins differently expressed in the serum of breast cancer patients vs. that of control individuals. Twenty-six microRNAs differentiate cancer tissue from healthy tissue, and 16 microRNAs differentiate the serum of cancer patients from that of the control group. The tissue expression of miR-99a, miR-497, miR-362, and miR-1274, and the serum levels of miR-141 correlated with patient survival. Moreover, the predictor consisting of miR-125b, miR-29c, miR-16, miR-1260, and miR-451 was able to differentiate breast cancer patients from controls. The predictor was validated in 20 new cases of breast cancer patients and tested in 60 volunteer women, assigning 11 out of 60 women to the cancer group. An association of low levels of miR-16 with a high content of CD44 protein in serum was found. Circulating microRNAs in serum can represent biomarkers for cancer prediction. Their clinical relevance and the potential use of the predictor here described are discussed., This work was supported by ISCIII (Instituto de Salud Carlos III) Ref. FIS PI15/01262, co-financed by the European Regional Development Fund (ERDF) and AECC Project GEC Ref. GC16173720CARR (ML). AF, YG-M, and CM were granted with P-FIS, VHIR, and iP-FIS fellowships, respectively.